Skip to main content

Boehringer Ingelheim Venture Fund — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

60
Companies
$836.9M
Total invested
$17.4M
Avg. check
11
Industries
Biotechnology 11Health Care 8Medical 6Therapeutics 5Oncology 2Biopharma 2+5 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4960 of 60
Optina Diagnostics
January 2022

Optina Diagnostics develops technology for the early detection of disease through the eye.

Artificial Intelligence (AI) · Saint Laurent$2.1M Series A
Rinri Therapeutics
May 2021

Rinri Therapeutics is a biotechnology company developing a novel cell-based therapy.

Biotechnology · Sheffield$4.5M Grant
Delonix Bioworks
March 2021

Delonix Bioworks is working on synthetic biology approaches to develop the next generation medical solutions for infectious diseases.

Biotechnology · Shanghai$14.0M Seed
Libra Therapeutics
September 2020

Libra Therapeutics is a biotechnology company.

Biotechnology · San Diego$29.0M Series A
Bodyport
August 2020

Predicting worsening fluid status in a single step.

Health Care · San Francisco$11.2M Series A
NBE-Therapeutics
January 2020

NBE-Therapeutics is a biotech company that develops oncology treatments for cancer patients.

Biotechnology · Basel$22.0M Series C
Metabomed
December 2019

Metabomed designs drugs that treats cancer.

Biopharma · Yavne$12.5M Series B
Amal Therapeutics
November 2018

Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva.

Biopharma · Geneva$32.6M Series B
Aelin Therapeutics
December 2017

Aelin Therapeutics is a provider of a biotherapeutics platform technology called pept-ins that are intended to harnesses.

Biotechnology · Leuven$31.8M Series A
Rigontec
September 2016

Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.

Biotechnology · Martinsried$16.9M Series A
STAT-Dx
April 2016

STAT-Dx is focused on the development of near-patient testing products for healthcare professionals.

Biotechnology · Barcelona$28.5M Series C
Vira Therapeutics
June 2015

ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic viruses.

Biotechnology · Innsbruck$4.0M Series A

Where Boehringer Ingelheim Venture Fund invests

Biotechnology11
Health Care8
Medical6
Therapeutics5
Oncology2
Biopharma2

About Boehringer Ingelheim Venture Fund's portfolio

How many companies has Boehringer Ingelheim Venture Fund invested in?

Boehringer Ingelheim Venture Fund has invested in 60 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Boehringer Ingelheim Venture Fund invest in?

Boehringer Ingelheim Venture Fund's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Oncology. The firm invests across 11 different industry categories.

What is Boehringer Ingelheim Venture Fund's largest investment?

Among tracked funding rounds, Amal Therapeutics received $32.6M in a Series B round. Boehringer Ingelheim Venture Fund's total known invested capital is $836.9M.

What is the average investment size for Boehringer Ingelheim Venture Fund?

Boehringer Ingelheim Venture Fund's average investment size is $17.4M across its portfolio of 60 companies.

What are Boehringer Ingelheim Venture Fund's most recent investments?

Recent Boehringer Ingelheim Venture Fund portfolio additions include Optina Diagnostics, Rinri Therapeutics, Delonix Bioworks, Libra Therapeutics, Bodyport. These companies were founded in 2020 or later.

Reach the founders behind these 60 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →